Recent studies indicate that combining TCM with PD-1/PD-L1 inhibitors can significantly improve median survival times for patients, undoubtedly providing new directions for cancer treatment, however, there remains a lack of sufficient large-sample prospective controlled studies to provide evidence supporting the combined treatment of traditional Chinese medicine and immune checkpoint inhibitors for tumors. The gene discussed is PDCD1; the disease is cancer.